These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 28452036)
61. Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients. Yu W; Yang X; Chu L; Zhao K; Chen H; Xiang J; Zhang Y; Li H; Zhao W; Sun M; Wei Q; Fu X; Xie C; Zhu Z Pathol Res Pract; 2018 Jul; 214(7):1017-1023. PubMed ID: 29729836 [TBL] [Abstract][Full Text] [Related]
62. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck. Machiels JP; Schmitz S Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545 [TBL] [Abstract][Full Text] [Related]
63. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131 [TBL] [Abstract][Full Text] [Related]
64. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. Feng Z; Guo W; Zhang C; Xu Q; Zhang P; Sun J; Zhu H; Wang Z; Li J; Wang L; Wang B; Ren G; Ji T; Tu W; Yang X; Qiu W; Mao L; Zhang Z; Chen W PLoS One; 2011; 6(10):e26399. PubMed ID: 22065993 [TBL] [Abstract][Full Text] [Related]
65. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017 [TBL] [Abstract][Full Text] [Related]
66. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Lavaf A; Genden EM; Cesaretti JA; Packer S; Kao J Cancer; 2008 Feb; 112(3):535-43. PubMed ID: 18076014 [TBL] [Abstract][Full Text] [Related]
67. Incidence and long-term survival of patients with de novo head and neck carcinoma after liver transplantation. Coordes A; Albers AE; Lenarz M; Seehofer D; Puhl G; Pascher A; Neuhaus R; Neuhaus P; Pratschke J; Andreou A Head Neck; 2016 May; 38(5):707-14. PubMed ID: 25521431 [TBL] [Abstract][Full Text] [Related]
68. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma. Pardo L; Valero C; López M; García J; Camacho M; Quer M; León X Auris Nasus Larynx; 2017 Jun; 44(3):313-318. PubMed ID: 27401121 [TBL] [Abstract][Full Text] [Related]
69. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. Christensen A; Kiss K; Lelkaitis G; Juhl K; Persson M; Charabi BW; Mortensen J; Forman JL; Sørensen AL; Jensen DH; Kjaer A; von Buchwald C BMC Cancer; 2017 Aug; 17(1):572. PubMed ID: 28841839 [TBL] [Abstract][Full Text] [Related]
70. High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: Risk Factors for Recurrence and Impact of Adjuvant Treatment. Trosman SJ; Zhu A; Nicolli EA; Leibowitz JM; Sargi ZB Laryngoscope; 2021 Jan; 131(1):E136-E143. PubMed ID: 32065413 [TBL] [Abstract][Full Text] [Related]
71. The EGFR-mTOR pathway and laryngeal cancer angiogenesis. Lionello M; Lovato A; Staffieri A; Blandamura S; Turato C; Giacomelli L; Staffieri C; Marioni G Eur Arch Otorhinolaryngol; 2014 Apr; 271(4):757-64. PubMed ID: 24065188 [TBL] [Abstract][Full Text] [Related]
72. The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study. Yang H; Cai YC; Cao Y; Song M; An X; Xia Y; Wei J; Jiang WQ; Shi YX Chin J Cancer; 2015 Sep; 34(12):614-21. PubMed ID: 26369827 [TBL] [Abstract][Full Text] [Related]
73. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis. Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481 [TBL] [Abstract][Full Text] [Related]
74. Postoperative radiotherapy dose requirement in standard combined-modality practice for head and neck squamous cell carcinoma: Analysis of salient surgical and radiotherapy parameters in 2 cohorts. Mohanti BK; Thakar A; Kaur J; Bahadur S; Malik M; Gandhi AK; Bhasker S; Sharma A Head Neck; 2017 Sep; 39(9):1788-1796. PubMed ID: 28586138 [TBL] [Abstract][Full Text] [Related]
75. pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. Qian X; Sinikovic B; Schreiber F; Ochsenreither S; Klinghammer K; Wollenberg B; Kaufmann AM; Albers AE Eur Arch Otorhinolaryngol; 2018 Nov; 275(11):2787-2795. PubMed ID: 30159726 [TBL] [Abstract][Full Text] [Related]
76. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ; Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998 [TBL] [Abstract][Full Text] [Related]
77. [Relationship between human papilloma virus infection and expression of p16 and EGFR in head and neck squamous cell carcinoma and their prognostic significance]. Ma L; Wang D; Wufuer A; Wu R; Zhang S; Wang R Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):23-8. PubMed ID: 24685082 [TBL] [Abstract][Full Text] [Related]
78. SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. De-Colle C; Menegakis A; Mönnich D; Welz S; Boeke S; Sipos B; Fend F; Mauz PS; Tinhofer I; Budach V; Abu Jawad J; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Belka C; Ganswindt U; Pigorsch S; Combs SE; Lohaus F; Linge A; Krause M; Baumann M; Zips D; Radiother Oncol; 2018 Jan; 126(1):125-131. PubMed ID: 29061496 [TBL] [Abstract][Full Text] [Related]
79. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686 [TBL] [Abstract][Full Text] [Related]
80. Connexin 43 (Cx43) Expression in Laryngeal Squamous Cell Carcinomas: Preliminary Data on Its Possible Prognostic Role. Puzzo L; Caltabiano R; Parenti R; Trapasso S; Allegra E Head Neck Pathol; 2016 Sep; 10(3):292-7. PubMed ID: 26748803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]